KCTD8 (potassium channel tetramerization domain containing 8) serves as an auxiliary subunit of GABA-B receptors that modulates receptor pharmacology and signaling kinetics 1 2. The protein contains a T1 tetramerization domain that binds to GABA-B2 subunits and an H2 homology domain that inhibits receptor desensitization, generating largely non-desensitizing receptor responses 1. KCTD8 slightly increases GABA affinity and can differentially modulate positive allosteric modulator responses due to its effects on G-protein signaling 2. Beyond GABA-B receptors, KCTD8 directly binds to and potentiates R-type Ca2+ channels (Cav2.3), particularly at presynaptic active zones in the habenula-interpeduncular pathway, where it bidirectionally modulates synaptic transmission independent of GABA-B receptor activation 3. Disease relevance includes associations with brain development under adverse prenatal conditions, where KCTD8 variants interact with maternal smoking exposure to influence cortical development in female adolescents 4. KCTD8 also functions as a tumor suppressor in hepatocellular carcinoma, where its epigenetic silencing through DNA methylation promotes malignancy via PI3K/AKT pathway activation 5. Additionally, KCTD8 variants show associations with type 2 diabetes susceptibility in Arab populations 6.